Nordic Migraine Symposium 2019

TEVA

Podcast by TEVA

Episodes

  1. US Anti-CGRP Guidelines and Clinical Experience With Anti-CGRP Antibodies – Andrew Blumenfeld

    06/19/2020

    US Anti-CGRP Guidelines and Clinical Experience With Anti-CGRP Antibodies – Andrew Blumenfeld

    The United States (US) perspective on the use of anti-CGRP monoclonal antibodies mAbs was presented by Andrew Blumenfeld. He discussed the US guidelines and the rationale for them. 1. American Headache Society. Headache 2019;59:1-18. 2. Serrano D et al. Headache 2015;55:502-518. 3. Louter MA et al. Brain. 2013;136(Pt 11):3489-3496. 4. Schwedt TJ et al. J Headache Pain 2018;19:38. 5. Lanteri-Minet M et al. Pain 2005;118:319-326. 6. Rossi P et al. Headache 2005;45:561-570. 7. Buse DC et al. Headache 2019;59:306-338. 8. Spanou I et al. Headache 2019;59:1174-1186. 9. Walker CS et al. Ann Clin Transl Neurol 2016;3:309-310 10. Hay DL et al. Bri J Pharmacol 2018;175:3-17 11. Tough IR et al. Neurogastroenterol Motil 2018;30:e13454. 12. Stauffer VL et al. JAMA Neurol 2018;75:1080-1088. 13. Skljarevski V et al. Cephalalgia 2018;38:1442-1454. 14. Tepper SJ et al. Headache 2018;59:276-290. 15. Ferrari MD et al. Lancet 2019:1-11.

    7 min
  2. EHF Anti-CGRP Treatment Recommendations – Lars Bendtsen

    06/19/2020

    EHF Anti-CGRP Treatment Recommendations – Lars Bendtsen

    As co-author of the European Headache Federation (EHF) guideline on the use of anti-CGRP monoclonal antibodies (mAbs) for migraine prevention, Lars Bendtsen presented an overview of the scientific basis for the recommendations. 1. Sacco et al. J Headache Pain 2019.

    5 min
  3. Acute and Preventative Treatments – Anna Sundholm

    06/19/2020

    Acute and Preventative Treatments – Anna Sundholm

    Anna Sundholm presented an overview of all currently available acute and preventative treatments for the different migraine patients, and how to use them most effectively. 1. Steiner TJ et al. J Headache Pain 2011;12:419-426. 2. Steiner TJ et al. J Headache Pain 2019;20:24. 3. Sundholm A et al. Lakartidningen 2020;117. pii: FTS7. 4. http://www.huvudvarkssallskapet.se/ Accessed December 2019. 5. Silberstein SD. CNS Spectrums 2017;22:4-12. 6. Cameron C et al. Headache 2015;55 Suppl 4:221-235. 7. Ong JJY et al. Neurotherapeutics 2015;15:274-290. 8. Lipton RB et al. JAMA 200;284:2599-2605. 9. Sculpher M et al. Pharmacoeconomics 2002;20:91-100. 10. Ferrari MD et al. Lancet 2001;358:1668-1675. 11. Freitag F et al. Headache 2008;48: 341-354. 12. Brandes JL et al. Cephalalgia 2005;25: 735-742. 13. Lipton RB et al. Headache 2017;57:1026-1040. 14. Brandes JL et al. JAMA 2007;297:1443-1454. 15. ICHD-3. Cephalalgia 2018;38:1-211. 16. Evers S et al. Eur J Neurol 2009;16:968-981. 17. Silberstein S et al. Headache 2009;49:1153-1162. 18. Aurora SK et al. Headache 2011;51:1358-1373. 19. Tepper SJ et al. Lancet Neurol 2017;16: 425-434. 20. Ruff DD et al. Cephalalgia 2019;39:931-944. 21. Ferrari MD et al. Lancet 2019;394:1030-1040. 22. Tfelt-Hansen P et al. CNS Drugs 2012;26:375-382.

    8 min
  4. Non-Pharmacological Treatments of Migraine – Jakob M. Hansen

    06/19/2020

    Non-Pharmacological Treatments of Migraine – Jakob M. Hansen

    Migraine is a multifactorial disease and many patients search for alternative, non-pharmacological treatments to get better. Jakob Hansen presented an overview of the currently available non-pharmacological treatments and the evidence that exists for their effectiveness. 1. Tfelt-Hansen et al. CNS Drugs 2012;26:375-382. 2. Probyn K et al. BMJ Open 2017;7:e016670. 3. Chaibi A et al. J Headache Pain 2011;12:127-133. 4. Posadzki P et al. Cephalalgia 2011;31:964-970. 5. Linde K et al. Cochrane Database Syst Rev 2016;6:CD001218. 6. Diener H-C et al. Lancet Neurol 2006;5:310-316. 7. Von Luckner A et al. Headache 2018;58:199-209.

    6 min
  5. The Clinical Data of Anti-CGRP Antibodies – Mikko Kallela

    06/19/2020

    The Clinical Data of Anti-CGRP Antibodies – Mikko Kallela

    Mikko Kallela presented an overview of the efficacy and safety of the currently available anti-CGRP antibodies erenumab, fremanezumab, galcanezumab and eptinezumab. 1. Dodick DW et al. Cephalalgia 2019;39:1075-1085. 2. Goadsby PJ et al. N Engl J Med 2017;377:2123-2132. 3. Dodick DW et al. Cephalalgia 2018;38:1026-37. 4. Tepper S et al. Lancet Neurol 2017;16:425-434. 5. Dodick DW et al. JAMA 2018;319:1999-2008. 6. Silberstein SD et al. N Engl J Med 2017;377:2113-2122. 7. Stauffer VL et al. JAMA Neurol 2018;75:1080-1088. 8. Skljarevski V et al. Cephalalgia 2018;38:1442-1454. 9. Detke HC et al. Neurology 2018;91:e2211-e21. 10. Saper J et al. Cephalalgia 2017;37:337. 11. Ashina M et al. Cephalalgia 2019;39:1455-1464. 12. Ning X et al. Neurology 2019;92(15 Supplement). 13. Ferrari MD et al. Lancet 2019;394:1030-1040.

    9 min
  6. CGRP – a Key Molecule in Primary Headaches – Lars Edvinsson

    06/19/2020

    CGRP – a Key Molecule in Primary Headaches – Lars Edvinsson

    Prof. Lars Edvinsson showed the audience how calcitonin gene-related peptide (CGRP) gradually became one of the most important molecules in primary headaches. From its discovery in the early 1980s to its role as an important target for novel specific anti-migraine drugs. 1. Edvinsson L et al. Brain Res Rev 2005;48:438-468. 2. Markowitz S et al. J Neurosci 1987;7:4129-4136. 3. Goldstein DJ et al. Cephalalgia 1997;17:785-790. 4. Amara SG et al. Nature 1982;298:240-244. 5. Rosenfeld MG et al. Science 1984;225:1315-1320. 6. Edvinsson L et al. Trends Neurosci 1985;8:126-131. 7. Uddman R et al. Neurosci Lett 1985;62:131-136. 8. McCulloch J et al. PNAS 1986;83:5731-5735. 9. Edvinsson L et al. Pharmacol Toxicol 2001;86:65-73. 10. Edvinsson L et al. Br J Pharmacol 1990;100:312-318. 11. Edvinsson L et al. Cephalalgia 1995;15:272-276. 12. Goadsby PJ et al. Ann Neurol 1988;23:193-196. 13. Edvinsson L et al. Neurotherapeutics 2010;7:164-175. 14. Goadsby PJ et al. Ann Neurol 1993;33:48-56. 15. Edvinsson L et al. Nat Rev Neurol 2018;14:338-350. 16. Liu Y et al. Cephalalgia 2009;29:935-948. 17. Eftekhari S et al. Brain Res 2015;1600:93-109. 18. Edvinsson L et al. Br J Clin Pharm 2015;80:193-199.

    8 min
  7. Raising Headache Awareness in General Practitioner and General Neurology Practice – Anne C. Poole

    06/19/2020

    Raising Headache Awareness in General Practitioner and General Neurology Practice – Anne C. Poole

    Anne Christine Poole passionately made an argument for raising awareness in the general practitioner (GP) and general neurology practice, in order to deliver the comprehensive and effective care that migraine patients need. For many patients that suffer from migraine, the disease is seriously disabling and can be extremely painful. As a consequence, a large number of patients with migraine don’t have the same opportunities in life as others have. Every year, migraine causes millions of days lost from work and school. 1. Miller S et al. Practitioner. 2014 Sep;258:19-24. 2. Oral communication by Dr Faisal Amin. 3. Hirtz D et al. Neurology 2007;67:326-337.

    4 min

  8. 06/19/2020

    Challenges in Clinical Practice – Lars Bendtsen

    In his lecture, Dr Lars Bendtsen provided the audience with his strategies to tackle the major clinical challenge in headache management: provide headache management of high quality to a large number of sufferers. These strategies include increasing awareness, increasing interest, optimizing the organization of headache care, and improving treatment possibilities.

    4 min
  9. Burden of Headache – Mattias Linde

    06/19/2020

    Burden of Headache – Mattias Linde

    Prof. Mattias Linde presented an overview of the incidence and prevalence of migraine, the dynamics of a migraine attack, and the consequences of migraine for both patients and society. 1. Merikangas KR et al. BMJ 2011;343:bmj.d5076. 2. https://www.who.int/mental_health/management/who_atlas_headache_disorders_results.pdf?ua=1. Accessed February 2020. 3. Linde M et al. Cephalalgia 2011;31:585-96. 4. Linde M et al. Cephalalgia 2004;24:455-465. 5. Linde M et al. Acta Neurol Scand 2006;114:71-83. 6. Linde M et al. Cephalalgia 2006;26:712-721. 7. GBD 2015 Neurological Disorders Collaborator Group. Lancet Neurol 2017;16:877-897. 8. Hjalte F et al. J Headache Pain 2019;20:65. 9. Linde M et al. Eur J Neurol 2012;19:703-e43.

    9 min
  10. Anti-CGRPs and Botox: Why, When and How? – Andrew Blumenfeld

    06/19/2020

    Anti-CGRPs and Botox: Why, When and How? – Andrew Blumenfeld

    In his second lecture, Andrew Blumenfeld presented the US treatment guidelines for onabotulinumtoxin A (botox) in migraine patients, its mechanism of action, and a summary of the most important US clinical data for this migraine treatment. 1. Whitcup SM et al. Ann NY Acad Sci 2014;1329:67-80. 2. Gazerani P et al. Pain 2009;141:60-69. 3. Aoki KR. Headache 2003;43:S9-15. 4. Jeynes LC et al. Pain Practice 2008;8:269-276. 5. Cui M et al. Pain 2004;107:125-133. 6. Gazerani P et al. Pain 2006;122:315-325. 7. Aurora SK et al. Headache 2011;51:1358-1373. 8. Blumenfeld A et al. J Headache Pain 2018;19:13. 9. Dodick DW et al. Cephalalgia 2019;39:945-956.

    5 min
  • 10 Episodes

About

Podcast by TEVA

Information